display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
atezolizumab plus bevacizumab IMbrave050

Study type: